Teschendorff, Andrew Lee, Shih-Han Jones, Allison Fiegl, Heidi Kalwa, Marie Wagner, Wolfgang Chindera, Kantaraja Evans, Iona Dubeau, Louis Orjalo, Arturo Horlings, Hugo Niederreiter, Lukas Kaser, Arthur Yang, Winnie Goode, Ellen Fridley, Brooke Jenner, Richard Berns, Els Wik, Elisabeth Salvesen, Helga Wisman, G. van der Zee, Ate Davidson, Ben Trope, Claes Lambrechts, Sandrina Vergote, Ignace Calvert, Hilary Jacobs, Ian Widschwendter, Martin Additional file 10: of HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer Kaplan-Meier survival estimates in patients from the BERGEN set who received no chemotherapy (untreated group, n  = 9) (a) or carboplatin-based chemotherapy (n  = 40) (b) and stratified according to HOTAIR expression. Patients (n = 49) treated in Bergen (Norway) and whose cancers had >25 % stroma component were analyzed; 8, 2, 34 and 5 had stage 1, 2, 3 and 4 disease, respectively; 32, 6, 9 and 2 had a serous, mucinous, endometrioid and clear cell cancer, respectively. In the untreated group, significantly more patients had stage 1 disease (44 % versus 10 % in the carboplatin group) and no residual disease after primary surgery (75 % versus 38 % in the carboplatin group). The top tertile expressing samples were deemed as high (positive) HOTAIR expressors and compared with low/absent (negative) HOTAIR expressors. There is no significant difference between high and low HOTAIR expressors with regards to grade, stage or residual disease. Comparing HOTAIR-positive with HOTAIR-negative patients, the hazard ratio is 2.55 (95 % confidence interval 1.14–5.68), P value 0.018. (PDF 244 kb) DNA methylation signature;BERGEN;cancer Kaplan-Meier survival estimates;carboplatin group;chemotherapy;HOTAIR expressors;PDF 244 kb 2015-10-24
    https://springernature.figshare.com/articles/journal_contribution/Additional_file_10_of___HOTAIR_and_its_surrogate_DNA_methylation_signature_indicate_carboplatin_resistance_in_ovarian_cancer/4452356
10.6084/m9.figshare.c.3639527_D9.v1